Cirki Nle R

Richard B. Brewer Joins Nile Therapeutics as Executive Chairman of the Board of Directors
SAN FRANCISCO, July 22 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced the appointment of Richard B.

Nile Therapeutics Completes Dosing of Phase II Study
SAN FRANCISCO, July 7 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced that it has completed the dosing of the last patient in NIL-CDNP-CT005, an open-label, single-blind, placebo-controlled Phase II study of CD-NP in patients with acute decompensated heart failure, or ADHF.

Nile Therapeutics Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
SAN MATEO, Calif., June 4 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced that, on June 1, 2010, the Company received a letter from The Nasdaq Stock Market indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, Nile was not in compliance with Marketplace Rule 5550(a)(2).

Cirki Nle R home site map
Richard B. Brewer Joins Nile Therapeutics as Executive Chairman of the Board of Directors SAN FRANCISCO, July 22 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced the appointment of Richard B. Nile Therapeutics Completes Dosing of Phase II Study SAN FRANCISCO, July 7 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced that it has completed the dosing of the last patient in NIL-CDNP-CT005, an open-label, single-blind, placebo-controlled Phase II study of CD-NP in patients with acute decompensated heart failure, or ADHF. Nile Therapeutics Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule SAN MATEO, Calif., June 4 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced that, on June 1, 2010, the Company received a letter from The Nasdaq Stock Market indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, Nile was not in compliance with Marketplace Rule 5550(a)(2).	Subscribe to our Monthly Email Newsletter Yehuda Diamonds Amends Lawsuit Against Blue Nile to Allege that Blue Nile Also Failed to Disclose that Its Treated Rubies Contain Synthetic Ruby and G Consumers who purchased rubies or jewelry containing a ruby from Blue Nile, Inc. were not notified that the gems have been treated and contain synthetic ruby and glass, according to an amended complaint filed in federal court yesterday by Yehuda Diamonds. Nile Cruise: An Exotic Cruise into a Bygone Historic Era A Nile Cruise is a wonderful way for a tourist to explore Egypt in a faster way, as one can really enjoy the numerous temples, monuments and museums. Moreover, the cruise ship becomes a place to get back to and relax after the hectic sightseeing. Cruising the Nile is very luxurious and comfortable. Moreover one is reliving the same experiences of the legendary historical people. Cleopatra sailed the Nile, Moses was floating in a boat of rushes as an infant in the Nile. Nile Therapeutics Reports 2010 First Quarter Financial Results SAN MATEO, Calif., May 14 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced its first quarter financial results for 2010. Financial Results For the three months ended March 31, 2010, Nile reported a net loss of approximately $1.9 million, or $0.07 per share, compared to a net loss of approximately $1.8 million, or $0.07 per share, during the first quarter of 2009. What Are The Symptoms Of West Nile Virus In Children? West Nile Virus is a disease spread by mosquitoes, the first occurrences of which appeared in the USA in 1999. The virus can be fatal to birds, horses and unfortunately humans too. If you are a parent and are worried about symptoms of West Nile Virus in children then you should be aware that the virus is much less likely to be contracted by children than it is by adults. Children with weak immune systems may be more at risk than other children.